Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MACK - Merrimack Pharmaceuticals Inc


Close
15.13
0   0%

Share volume: 1,255,765
Last Updated: Fri 17 May 2024 10:00:00 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$15.13
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
35%
Profitability 23%
Dept financing 7%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
Performance
5 Days
1.25%
1 Month
3.05%
3 Months
-4.40%
6 Months
2.01%
1 Year
180.18%
2 Year
126.87%
Key data
Stock price
$15.13
P/E Ratio 
0.00
DAY RANGE
$15.13 - $15.16
EPS 
$0.00
52 WEEK RANGE
$3.00 - $13.66
52 WEEK CHANGE
$1.85
MARKET CAP 
174.143 M
YIELD 
N/A
SHARES OUTSTANDING 
14.321 M
DIVIDEND
$1.4967
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$101,203
AVERAGE 30 VOLUME 
$78,050
Company detail
CEO:
Region: US
Website: merrimack.com
Employees: 54
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Recent news